Cell therapy is therapy in which cellular material is injected into a patient; this generally means intact, living cells. For example, T cells capable of fighting cancer cells via cell-mediated immunity may be injected in the course of immunotherapy.
Therapies that activate the host immune system have shown tremendous promise for a wide variety of solid tumors. However, in most cancer types, fewer than half of patients respond to these th...
There are many tumor biomarkers but, they mostly reflect tumor mass or past growth, when what is more important is to obtain an indication of future growth and therapy response.Proliferat...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...
Pluripotent stem cells can reproduce indefinitely and develop into any cell type in the body. We are putting pluripotent stem cells to use, for a neuron replacement therapy for Parkinso...
DATE: January 25, 2018TIME: 10:00am PST, 1:00pm EST, 6:00pm GMTOncolytic virotherapy, the use of viral vectors to treat cancer, holds huge promise. Viruses are natural DNA delivery vehi...
DATE: January 25, 2018TIME: 8:00AM PST, 10:00AM CSTProstate cancer (PCa) is the most common noncutaneous malignancy in men in the US. A significant fraction of advanced PCa treate...
DATE: December 14, 2017TIME: 05:00am PST, 08:00am EST, 2:00pm CETvon Willebrand Disease (vWD) is one of the most common congenital bleeding disorders, affecting ~1%* of the world’...
DATE: November 29, 2017TIME: 10:00 AM PSTThe three human RAS genes (HRAS, KRAS and NRAS) encode four highly related RAS small GTPases (HRAS, KRAS4A, KRAS4B and NRAS). RAS proteins funct...
DATE: November 16, 2017TIME: 9:00AM PT, 12:00PM ETThe wide use of 2D monolayer cultures for cancer drug discovery reflects the technical ease of implementation for drug screening, and t...
Derivation of many different cell types from human pluripotent stem cells (embryonic stem cells or HESCs and induced pluripotent stem cells or hiPS cells) is an area of growing interest both ...
DATE: November 7, 2017 TIME: 10:00AM PSTChimeric Antigen Receptor (CAR)-transduced T lymphocytes have demonstrated impressive clinical activity against B cell malignancies in...
DATE: October 26, 2017TIME: 12:00 PM PDTThis presentation will focus on recent advances in cellular therapy—from mesenchymal stromal cells (MSCs) to tumor-specific T-cells. More s...
DATE: October 19, 2017TIME: 08:00am PDT, 11:00am EDT Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than...
Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T c...
DATE: October 17, 2017TIME: 08:00am PDT, 11:00am EDTResearching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an in...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
The detection of CTCs has been used as useful biomarkers in prognosis and monitoring therapeutic response of patients with metastatic cancer. However, during the course of cancer therapy, CTC...
Colorectal cancer (CRC) is the third most common cancer among Americans, and the second deadliest. Its pathogenesis results from an interplay between environmental factors that influence biol...
We developed two computational methods, CARE and TIDE, to predict response and resistance to targeted therapies and immunotherapies. CARE infers gene signatures of targeted therapy response b...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
The “R2G2” (B6;129-Rag2tm1FwaIL2rgtm1Rsky/DwlHsd) knockout mouse is the latest advancement to provide an alternative option in the highly immunodeficient mouse model category for...
There has been a great deal of renewed attention in immuno-oncology over the last decade. Therapies for cancer are being developed, approved, and administered that can either initiate,...
DATE: October 10, 2017TIME: 9:00AM PDTPatient-derived xenografts (PDX) are increasingly being used in biomedical research for therapeutic analysis in mice. Unlike traditional cell line...
Therapies that activate the host immune system have shown tremendous promise for a wide variety of solid tumors. However, in most cancer types, fewer than half of patients respond to these th...
There are many tumor biomarkers but, they mostly reflect tumor mass or past growth, when what is more important is to obtain an indication of future growth and therapy response.Proliferat...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...
Pluripotent stem cells can reproduce indefinitely and develop into any cell type in the body. We are putting pluripotent stem cells to use, for a neuron replacement therapy for Parkinso...
DATE: January 25, 2018TIME: 10:00am PST, 1:00pm EST, 6:00pm GMTOncolytic virotherapy, the use of viral vectors to treat cancer, holds huge promise. Viruses are natural DNA delivery vehi...
DATE: January 25, 2018TIME: 8:00AM PST, 10:00AM CSTProstate cancer (PCa) is the most common noncutaneous malignancy in men in the US. A significant fraction of advanced PCa treate...
DATE: December 14, 2017TIME: 05:00am PST, 08:00am EST, 2:00pm CETvon Willebrand Disease (vWD) is one of the most common congenital bleeding disorders, affecting ~1%* of the world’...
DATE: November 29, 2017TIME: 10:00 AM PSTThe three human RAS genes (HRAS, KRAS and NRAS) encode four highly related RAS small GTPases (HRAS, KRAS4A, KRAS4B and NRAS). RAS proteins funct...
DATE: November 16, 2017TIME: 9:00AM PT, 12:00PM ETThe wide use of 2D monolayer cultures for cancer drug discovery reflects the technical ease of implementation for drug screening, and t...
Derivation of many different cell types from human pluripotent stem cells (embryonic stem cells or HESCs and induced pluripotent stem cells or hiPS cells) is an area of growing interest both ...
DATE: November 7, 2017 TIME: 10:00AM PSTChimeric Antigen Receptor (CAR)-transduced T lymphocytes have demonstrated impressive clinical activity against B cell malignancies in...
DATE: October 26, 2017TIME: 12:00 PM PDTThis presentation will focus on recent advances in cellular therapy—from mesenchymal stromal cells (MSCs) to tumor-specific T-cells. More s...
DATE: October 19, 2017TIME: 08:00am PDT, 11:00am EDT Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than...
Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T c...
DATE: October 17, 2017TIME: 08:00am PDT, 11:00am EDTResearching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an in...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
The detection of CTCs has been used as useful biomarkers in prognosis and monitoring therapeutic response of patients with metastatic cancer. However, during the course of cancer therapy, CTC...
Colorectal cancer (CRC) is the third most common cancer among Americans, and the second deadliest. Its pathogenesis results from an interplay between environmental factors that influence biol...
We developed two computational methods, CARE and TIDE, to predict response and resistance to targeted therapies and immunotherapies. CARE infers gene signatures of targeted therapy response b...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
The “R2G2” (B6;129-Rag2tm1FwaIL2rgtm1Rsky/DwlHsd) knockout mouse is the latest advancement to provide an alternative option in the highly immunodeficient mouse model category for...
There has been a great deal of renewed attention in immuno-oncology over the last decade. Therapies for cancer are being developed, approved, and administered that can either initiate,...
DATE: October 10, 2017TIME: 9:00AM PDTPatient-derived xenografts (PDX) are increasingly being used in biomedical research for therapeutic analysis in mice. Unlike traditional cell line...
Follow
